

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20201 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/084,542	05/26/1998	GREGORY D. VITE	LD125B	5662
23914	7590 05/20/2002			
STEPHEN B. DAVIS			EXAMINER	
BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT			KIFLE, BRUCK	
	P O BOX 4000 PRINCETON, NJ 08543-4000		ART UNIT	PAPER NUMBER
	,		1624	0 :
	·		DATE MAILED: 05/20/2002	le de

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/084,542

Applicant(s)

Examiner

Bruck Kifle, Ph.D.

Art Unit 1624

Vite et al.



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) X Responsive to communication(s) filed on *Mar 5, 2002* 2a) This action is **FINAL**. 2b) X This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11: 453 O.G. 213. Disposition of Claims 4) X Claim(s) 1-4, 7, 8, 11, and 14-67 is/are pending in the application. 4a) Of the above, claim(s) ______ is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) X Claim(s) <u>1-4, 7, 8, 11, and 14-67</u> is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claims ______ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) \square All b) \square Some* c) \square None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) The translation of the foreign language provisional application has been received. 15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6) Other:

Art Unit: 1624

Applicant's amendments and remarks filed 3/5/02 have been received and reviewed.

Claims 1-4, 7, 8, 11 and 14-67 are now pending in this application. Applicant's election of the compound of example 3 is acknowledged. This compound is allowable.

Claim Rejections - 35 USC § 112

Claims 1, 2, 4, 7, 8 and 15-58 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The term "substituted" without saying which substituents are intended is still indefinite. One skilled in the art can still not say which substituents are permitted and which ones are not. Applicants arguments have been fully considered. However, Applicants are reminded that although the claims are interpreted in light of the specification, critical limitations from the specification cannot be read into the claims (see, e.g., In re Van Guens, 988 F.2d 1181, 26 PSPG2d 1057 (Ded. Cir. 1991)). Accordingly, without the recitation of all these critical limitations, the claims do not adequately define the instant invention.

Claims 4, 7, 8, 11, 15, 23, 25, 27, 29 and 31-67 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating breast, ovarian and colon cancers, does not reasonably provide enablement for treating any and all other cancers embraced by the claims. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Application/Control Number: 09/084,542

Art Unit: 1624

In re Buting 163 USPQ 689 establishes that even clinical tests showing that a compound

found to be useful in the treatment of two types of cancers was not sufficient for a much broader

range.

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Bruck Kifle whose telephone number is (703) 305-4484.

The fax phone number for this Group is (703) 308-4556 or (703) 305-3592. Any inquiry

of a general nature or relating to the status of this application or proceeding should be directed to

the Group receptionist whose telephone number is (703) 308-1235.

May 17, 2002

Primary Examiner

Page 3

Art Unit 1624